ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 90

Influence of Susceptible HLA-DRB1 Alleles on Clinical Subphenotypes of Systemic Lupus Erythematosus in Koreans

So-Young Bang1, Ji-Young Choi1, Songree Park1, Seung Lee2, Jeongim Choi1, Seung-Jae Hong3, Hye-Soon Lee1, Chan-Bum Choi1 and Sang-Cheol Bae1, 1Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3Kyung Hee University Hospital, seoul, South Korea

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Human leukocyte antigens (HLA) and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Genetics, Genomics and Proteomics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We investigated the association between human leukocyte antigen (HLA)-DRB1 alleles and systemic lupus erythematosus (SLE) susceptibility and whether each allele has a significant effect on clinical manifestations and autoantibody profiles in a Korean population.

Methods: All SLE patients (n=1,089) and control subjects (n=2,161) were Korean. We performed a two-stage analysis in a discovery set (group 1: 475 SLE and 1,119 controls) and a replication set (group 2: 614 SLE and 1,072 controls) using high-resolution HLA-DRB1 typing. The odds ratio (OR) of risk alleles associated with SLE was calculated by a regression method, which was adjusted for age, sex, and disease duration.

Results: We found that four HLA-DRB1 alleles [two confirmed alleles; *15:01 (P=1.11×10-13), *09:01 (P=1.59×10-5), two novel alleles; *08:03 (P=8.80×10-8), *07:01 (P=1.14×10-6)] and were associated with susceptibility to SLE. Double copies of these risk alleles (OR 3.38) were associated with a higher risk of developing SLE than a single copy (OR 1.95), showing additive genetic effects. In addition, three novel HLA-DRB1*12:02 (P=6.35×10-4), *11:01 (P=1.24×10-3), *13:02 (P=8.88×10-3) alleles were significantly protective against SLE. The HLA-DRB1*15:01 allele alone (OR 2.20) and double-copies of risk alleles (OR 3.71) increased the risk for anti-Sm production. In addition, SLE patients with double-copies of risk alleles showed more diverse clinical manifestations.

Conclusion: We demonstrated that four HLA–DRB1 risk alleles were associated with SLE in a Korean population, and also promote the production of anti-Sm and diverse clinical manifestations


Disclosure: S. Y. Bang, None; J. Y. Choi, None; S. Park, None; S. Lee, None; J. Choi, None; S. J. Hong, None; H. S. Lee, None; C. B. Choi, None; S. C. Bae, None.

To cite this abstract in AMA style:

Bang SY, Choi JY, Park S, Lee S, Choi J, Hong SJ, Lee HS, Choi CB, Bae SC. Influence of Susceptible HLA-DRB1 Alleles on Clinical Subphenotypes of Systemic Lupus Erythematosus in Koreans [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/influence-of-susceptible-hla-drb1-alleles-on-clinical-subphenotypes-of-systemic-lupus-erythematosus-in-koreans/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/influence-of-susceptible-hla-drb1-alleles-on-clinical-subphenotypes-of-systemic-lupus-erythematosus-in-koreans/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology